Shire gives attention to deficit of comparative data in ADHD and beyond

In what is destined to become a mantra for specialty biopharmaceutical company Shire across a range of its products, the company plans to identify the value differential of its treatment for attention deficit hyperactivity disorder Vyvanse against a competitor, Johnson & Johnson's Concerta.

Shire will conduct two Phase IV studies comparing Vyvanse (lisdexamfetamine dimesylate) with Concerta (methylphenidate HCl extended release tablets). The trials, involving a total of around 1000 patients, will produce...